NicOx conserves funds following naproxcinod disappointment
This article was originally published in Scrip
Executive Summary
In light of the recent setback with its lead candidate naproxcinod, NicOx is "reviewing all aspects of its cost base to ensure careful conservation of its funds" and as a result has decided to delay the start of a Phase II study of its next in-house product candidate NCX 6560 until clarification of naproxcinod's regulatory position.